Modulation of Cisplatin Sensitivity through TRPML1-Mediated Lysosomal Exocytosis in Ovarian Cancer Cells: A Comprehensive Metabolomic Approach
Cells · 08.01.2024 · 13 (2) · 115
DOI: 10.3390/cells13020115 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, online erschienen am 08.01.2024. Verfasst von Boyun Kim und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of SmartBio, College of Life and Health Science, Kyungsung University, Busan 48434, Republic of Korea. Hauptthemen laut MEDLINE: Cisplatin, Exocytosis, Ovarian Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korea Basic Science Institute, National Research Foundation of Korea, Ministry of Education.
Abstract (Originalsprache)
Background
The lysosome has emerged as a promising target for overcoming chemoresistance, owing to its role in facilitating the lysosomal sequestration of drugs. The lysosomal calcium channel TRPML1 not only influences lysosomal biogenesis but also coordinates both endocytosis and exocytosis. This study explored the modulation of cisplatin sensitivity by regulating TRPML1-mediated lysosomal exocytosis and identified the metabolomic profile altered by TRPML1 inhibition.
Methods
We used four types of ovarian cancer cells: two cancer cell lines (OVCAR8 and TOV21G) and two patient-derived ovarian cancer cells. Metabolomic analyses were conducted to identify altered metabolites by TRPML1 inhibition.
Results
Lysosomal exocytosis in response to cisplatin was observed in resistant cancer cells, whereas the phenomenon was absent in sensitive cancer cells. Through the pharmacological intervention of TRPML1, lysosomal exocytosis was interrupted, leading to the sensitization of resistant cancer cells to cisplatin treatment. To assess the impact of lysosomal exocytosis on chemoresistance, we conducted an untargeted metabolomic analysis on cisplatin-resistant ovarian cancer cells with TRPML1 inhibition. Among the 1446 differentially identified metabolites, we focused on 84 significant metabolites. Metabolite set analysis revealed their involvement in diverse pathways.
Conclusions
These findings collectively have the potential to enhance our understanding of the interplay between lysosomal exocytosis and chemoresistance, providing valuable insights for the development of innovative therapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of SmartBio, College of Life and Health Science, Kyungsung University, Busan 48434, Republic of Korea.
- WCU Biomodulation, Department of Agricultural Biotechnology, Seoul National University, Seoul 08826, Republic of Korea.
- Cancer Research Institute, College of Medicine, Seoul National University, Seoul 03080, Republic of Korea.
- Department of Obstetrics and Gynecology, College of Medicine, Seoul National University, Seoul 03080, Republic of Korea.
ORCID-Profile: Boyun Kim, Yong Sang Song
Förderung
- Korea Basic Science Institute
- National Research Foundation of Korea
- Ministry of Education
Zitieren
APA
Kim, B., Kim, G., Kim, H., Song, Y. S., & Jung, J. (2024). Modulation of Cisplatin Sensitivity through TRPML1-Mediated Lysosomal Exocytosis in Ovarian Cancer Cells: A Comprehensive Metabolomic Approach. Cells, 13(2), 115. https://doi.org/10.3390/cells13020115
Vancouver
Kim B, Kim G, Kim H, Song YS, Jung J. Modulation of Cisplatin Sensitivity through TRPML1-Mediated Lysosomal Exocytosis in Ovarian Cancer Cells: A Comprehensive Metabolomic Approach. Cells. 2024;13(2):115. doi:10.3390/cells13020115
BibTeX
@article{Kim2024,
author = {Kim, Boyun and Kim, Gaeun and Kim, Heeyeon and Song, Yong Sang and Jung, Jewon},
title = {Modulation of Cisplatin Sensitivity through TRPML1-Mediated Lysosomal Exocytosis in Ovarian Cancer Cells: A Comprehensive Metabolomic Approach},
journal = {Cells},
year = {2024},
volume = {13},
number = {2},
pages = {115},
doi = {10.3390/cells13020115}
}
EUVIMED